vimarsana.com

Nancy Perlman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Promising ALS Therapy Moves Closer to Clinic

An experimental drug first tried at Columbia University Irving Medical Center as a last-ditch effort to help a 25-year-old woman with juvenile ALS is

United statesJaci hermstadAlexanderk lyashchenkoTom klingensteinVladislava korobeynikovNeil shneiderNancy perlmanColumbia university irving medical centerJean pape adams charitable foundationTow foundationDepartment of neurologyDrug administrationPaymaan jafar nejad ionis pharmaceuticalsLeipzig universityNational institute of neurological disordersClaire tow associate professor

Novel experimental drug designed to silence FUS gene may help treat ALS

Using an experimental drug, researchers were able to suppress a mutated amyotrophic lateral sclerosis (ALS) gene.

New yorkUnited statesColumbia universityTom klingensteinLou gehrigNeil shneiderNancy perlmanEmily hendersonJean pape adams charitable foundationCenter at columbia universityNational institutes of healthDrug administrationYork brain bankNational institute for neurological disordersNature medicineNational institute

Silencing a faulty gene may uncover clues to rare forms of ALS

Using an experimental drug, researchers were able to suppress a mutated amyotrophic lateral sclerosis (ALS) gene. Studies in mice demonstrate that the

New yorkUnited statesColumbia universityTom klingensteinLou gehrigNeil shneiderNancy perlmanJean pape adams charitable foundationCenter at columbia universityNational institutes of healthDrug administrationYork brain bankNational institute for neurological disordersNature medicineNational instituteNeurological disorders

Silencing a faulty gene may uncover clues to rare forms of ALS

NIH-funded preclinical study identifies potential therapeutic approach to treat ALS.

New yorkUnited statesColumbia universityTom klingensteinLou gehrigNeil shneiderNancy perlmanJean pape adams charitable foundationUs department of healthHuman servicesCenter at columbia universityNational institutes of healthDrug administrationDiscovery into healthYork brain bankNational institute for neurological disorders

BiologyWorks k(now)™ COVID-19 Clinical Trial Matches 99 1% Accuracy to RT-PCR Tests

BiologyWorks™, Inc., a digital healthcare platform company, today announced that a substantive clinical trial of its handheld, reusable molecular test for COVID-19 matched 99.1% accuracy to laboratory RT-PCR tests.

United statesNoord hollandLos angeles countyLos angelesNancy perlmanUniversity of californiaLos angeles county department of health servicesMelinda gates foundationHealth insurance portabilityAlfred mann foundationOur companyBusiness wireLocus medicusLos angeles county departmentHealth servicesSouthern california

vimarsana © 2020. All Rights Reserved.